Frédéric Baribaud

8.5k total citations · 1 hit paper
67 papers, 4.2k citations indexed

About

Frédéric Baribaud is a scholar working on Immunology, Virology and Epidemiology. According to data from OpenAlex, Frédéric Baribaud has authored 67 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 22 papers in Virology and 12 papers in Epidemiology. Recurrent topics in Frédéric Baribaud's work include HIV Research and Treatment (22 papers), Immune Cell Function and Interaction (19 papers) and Immunotherapy and Immune Responses (18 papers). Frédéric Baribaud is often cited by papers focused on HIV Research and Treatment (22 papers), Immune Cell Function and Interaction (19 papers) and Immunotherapy and Immune Responses (18 papers). Frédéric Baribaud collaborates with scholars based in United States, United Kingdom and Germany. Frédéric Baribaud's co-authors include Robert W. Doms, Stefan Pöhlmann, George J. Leslie, James A. Hoxie, Terri G. Edwards, Paul Bates, Graham Simmons, Elizabeth J. Soilleux, Frank Mortari and George Lin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and The Journal of Immunology.

In The Last Decade

Frédéric Baribaud

66 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR

2003 309 citations Stefan Pöhlmann, Frédéric Baribaud et al. profile →

Peers

Countries citing papers authored by Frédéric Baribaud

Since Specialization

Citations

This map shows the geographic impact of Frédéric Baribaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Baribaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Baribaud more than expected).

Fields of papers citing papers by Frédéric Baribaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Baribaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Baribaud. The network helps show where Frédéric Baribaud may publish in the future.

Co-authorship network of co-authors of Frédéric Baribaud

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Baribaud. A scholar is included among the top collaborators of Frédéric Baribaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Baribaud. Frédéric Baribaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	POS1129 IN VITRO EVIDENCE DEMONSTRATES THAT AFIMETORAN (BMS-986256), AN EQUIPOTENT TLR7/8 DUAL ANTAGONIST, HAS STEROID-SPARING POTENTIAL IN THE CLINIC 2023 ·Annals of the Rheumatic Diseases ·Qihong Zhao, (unknown), Gary L. Schieven, Hong Qiu, Rui Zhang, Mary Ellen Cvijic, (unknown), Manoj Chiney, Diane E. Shevell, Ihab Girgis, Frédéric Baribaud, (unknown), (unknown)	1
2	Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study 2023 ·ERJ Open Research ·Lydia Finney, (unknown), Dexter Wiseman, Anthony Rowe, Matthew J. Loza, Patrick Branigan, Christopher S. Stevenson, Frédéric Baribaud, Jadwiga A. Wedzicha, Ioannis Pandis, Gavin C. Donaldson	1
3	Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics 2020 ·Contemporary Clinical Trials Communications ·Chad K. Porter, Mark S. Riddle, Renée M. Laird, Matthew J. Loza, Suzanne Cole, (unknown), (unknown), Ramiro L. Gutiérrez, Frédéric Baribaud, Navin Rao, Sunil Nagpal	7
4	I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment 2019 ·PLoS Computational Biology ·Stelios Pavlidis, Calixte S. Monast, Matthew J. Loza, Patrick Branigan, (unknown), Ian M. Adcock, Yike Guo, Anthony Rowe, Frédéric Baribaud	16
5	Molecular surrogates of histologic activity in Crohn′s disease 2017 ·Journal of Cancer Science & Therapy ·Frédéric Baribaud	2
6	Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study 2016 ·Respiratory Research ·Matthew J. Loza, Ratko Djukanović, Kian Fan Chung, Daniel Horowitz, (unknown), (unknown), Elliot S. Barnathan, Vedrana S. Susulic, Philip E. Silkoff, Peter J. Sterk, Frédéric Baribaud	92
7	Systemic corticosteroid-associated serum analyte profiles in the U-BIOPRED severe asthma cohort 2015 ·Matthew J. Loza, Stelios Pavlidis, Anthony Rowe, Ratko Djukanović, Peter J. Sterk, Ian M. Adcock, Frédéric Baribaud, Kian Fan Chung	1
8	Divergent Gene Activation in Peripheral Blood and Tissues of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis following Infliximab Therapy 2014 ·PLoS ONE ·Alexander F. Rosenberg, (unknown), Yahui Grace Chiu, Rebecca Bolce, Darren Tabechian, (unknown), (unknown), Frédéric Baribaud, (unknown), Nancy J. Peffer, David J. Shealy, Edward M. Schwarz, Christopher T. Ritchlin	14
9	Determining the extent to which clinically effective treatment, ustekinumab or etanercept, reverses the molecular disease profile of psoriatic skin: comparisons of lesional, non-lesional and normal skin (34.5) 2010 ·The Journal of Immunology ·Carrie Brodmerkel, Katherine Li, Frédéric Baribaud, Mayte Suárez‐Fariñas, James G. Krueger	1
10	Femorotibial subchondral bone area and regional cartilage thickness: A cross‐sectional description in healthy reference cases and various radiographic stages of osteoarthritis in 1,003 knees from the Osteoarthritis Initiative 2010 ·Arthritis Care & Research ·R. Frobell, Michael C. Nevitt, M. Hudelmaier, W. Wirth, Bradley T. Wyman, Olivier Bénichou, D. Dreher, Richard Davies, Jennifer H. Lee, Frédéric Baribaud, Alberto Gimona, F. Eckstein	62
11	Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2 2009 ·Biochemical and Biophysical Research Communications ·Niu Shin, Frédéric Baribaud, Kathy Wang, Genjie Yang, (unknown), Maryanne Covington, Patricia Feldman, Karen Gallagher, Lynn Leffet, Yvonne Lo, Anlai Wang, Chu‐Biao Xue, Robert Newton, Peggy Scherle	21
12	Analysis of the Interaction of Ebola Virus Glycoprotein with DC‐SIGN (Dendritic Cell–Specific Intercellular Adhesion Molecule 3–Grabbing Nonintegrin) and Its Homologue DC‐SIGNR 2007 ·The Journal of Infectious Diseases ·Andrea Marzi, Peggy Möller, Sheri L. Hanna, Thomas Harrer, (unknown), Alexander Steinkasserer, Stephan Becker, Frédéric Baribaud, Stefan Pöhlmann	70
13	A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo 2006 ·Virology ·Stefan Pöhlmann, Jan Münch, (unknown), Jacqueline D. Reeves, Claas Otto, George J. Leslie, Heike Hofmann, Bridget A. Puffer, Frédéric Baribaud, Andrea Marzi, Thomas Gramberg, Zhiwei Chen, Nicole Stolte, Peter ten Haaft, Jonathan L. Heeney, Christiane Stahl‐Hennig, Kerstin Mätz‐Rensing, Thomas Schneider, Robert W. Doms, Frank Kirchhoff	3
14	Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus 2004 ·Virology ·Claude Krummenacher, Frédéric Baribaud, Manuel Ponce de Leon, (unknown), J. Charles Whitbeck, Ruliang Xu, Gary H. Cohen, Roselyn J. Eisenberg	115
15	The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? 2002 ·Expert Opinion on Therapeutic Targets ·Frédéric Baribaud, Robert W. Doms, Stefan Pöhlmann	46
16	DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells 2002 ·Virology ·Graham Simmons, Jacqueline D. Reeves, (unknown), Luk H. Vandenberghe, Frédéric Baribaud, J. Charles Whitbeck, Emily Burke, Michael J. Buchmeier, Elizabeth J. Soilleux, James L. Riley, Robert W. Doms, Paul Bates, Stefan Pöhlmann	299
17	Safe Use of the CXCR4 Inhibitor ALX40-4C in Humans 2001 ·AIDS Research and Human Retroviruses ·Benjamin J. Doranz, L G Filion, Francisco Díaz‐Mitoma, Daniel Sitar, Jan Sahai, Frédéric Baribaud, Michael J. Orsini, Jeffrey Benovic, D. William Cameron, Robert W. Doms	89
18	Extrafollicular Plasmablast B Cells Play a Key Role in Carrying Retroviral Infection to Peripheral Organs 2001 ·The Journal of Immunology ·Daniela Finke, Frédéric Baribaud, Heidi Diggelmann, Hans Acha‐Orbea	31
19	The Role of DC-SIGN and DC-SIGNR in HIV and SIV Attachment, Infection, and Transmission 2001 ·Virology ·Frédéric Baribaud, Stefan Pöhlmann, Robert W. Doms	72
20	Expression and Coreceptor Function of APJ for Primate Immunodeficiency Viruses 2000 ·Virology ·Bridget A. Puffer, Matthew Sharron, Christina Coughlan, Frédéric Baribaud, Carrie M. McManus, Benhur Lee, (unknown), (unknown), Richard Horuk, Monica Tsang, Robert W. Doms	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact